

FIG.1A




FIG.1B




FIG.1C




FIG.1D




FIG.2

Interaction of Bak with GST-Bcl-x<sub>L</sub> *in vitro*



FIG.3A

Interaction of Bak with Bcl-x<sub>L</sub> in COS cells




FIG.3B




FIG.4




FIG. 5

<u>PLASMID</u>	<u>RAT-1 CELL KILLING ACTIVITY</u>	<u>Bcl-X<sub>L</sub> BINDING ACTIVITY</u>
Bak	+	+
Bak ΔPS	+/-	-/+
Bak ΔGD	-	-
Bax	+	+
Bax ΔGD	-	-
Bip1a	+	+
Bip1a ΔGD	+/-	-

FIG.6




FIG.7

Bak

1. 220 \* 230 \* 240 \* 250 \* 260 \* 270 \*  
 CAG GTG GGA CGG CAG CTC GCC ATC ATC GGG GAC GAC ATC AAC CGA CGC TAT GAC TCA  
 Z3 Q V G R Q L A I I G D D I N R R Y D S

280 \* 290 \* 300 \*  
 GAG TTC CAG ACC ATG TTG CAG CAC CTG CAG CCC ACG  
 E F Q T M L Q H L Q P T 103

[SEQ. ID NO: 15]  
 [SEQ. ID NO: 16]

3

2. 200 \* 210 \* 220 \* 230 \* 240 \* 250 \*  
 CCT AGC AGC ACC ATG GGG CAG GTG GGA CGG CAG CTC GCC ATC ATC GGG GAC GAC ATC  
 6Z P S S T M G Q V G R Q L A I I G D D I

260 \* 270 \* 280 \*  
 AAC CGA CGC TAT GAC TCA GAG TTC CAG  
 N R R Y D S E F Q 94

[SEQ. ID NO: 17]  
 [SEQ. ID NO: 18]

2

3. 220 \* 230 \* 240 \* 250 \* 260 \*  
 GTG GGA CGG CAG CTC GCC ATC ATC GGG GAC GAC ATC AAC CGA CGC  
 Z4 V G R Q L A I I G D D I N R R 88

[SEQ. ID NO: 19]  
 [SEQ. ID NO: 20]

10

FIG. 8A



4. GGG GAC GAC ATC AAC CGA CGC TAT GAC TCA GAG TTC CAG [SEQ. ID NO: 21]  
 82 G D D I N R R Y D S E F Q 94 [SEQ. ID NO: 22]

Bax

160 \* 170 \* 180 \* 190 \* 200 \* 210 \*  
 5. CAG GAT GCG TCC ACC AAG AAG CTG AGC GAG TGT CTC AAG CGC ATC GGG GAC GAA CTG  
 52 Q D A S T K K L S E C L K R I G D E L

220 \* 230 \*  
 GAC AGT AAC ATG GAG CTG CAG  
 D S N M E L Q ZZ

[SEQ. ID NO: 23]  
 [SEQ. ID NO: 24]

180 \* 190 \* 200 \* 210 \*  
 6. CTG AGC GAG TGT CTC AAG CGC ATC GGG GAC GAA CTG GAC AGT AAC  
 52 L S E C L K R I G D E L D S N Z3

[SEQ. ID NO: 25]  
 [SEQ. ID NO: 26]

FIG. 8B

190 \* 200 \* 210 \*  
 7. CTC AAG CGC ATC GGG GAC GAA CTG GAC  
 53 L K R I G D E L D Z1

[SEQ. ID NO: 27]  
 [SEQ. ID NO: 28]

Bipla

150 \* 160 \* 170 \* 180 \* 190 \* 200 \*  
 8. TGC ATG GAG GGC AGT GAC GCA TTG GCC CTG CGG CTG GCC TGC ATC GGG GAC GAG ATG  
 50 C M E G S D A L A L R L A C I G D E M

210 \* 220 \* 230 \*  
 GAC GTG AGC CTC AGG GCC CCG CGC CTG  
 D V S L R A P R L ZZ

[SEQ. ID NO: 29]  
 [SEQ. ID NO: 30]

170 \* 180 \* 190 \* 200 \* 210 \*  
 9. TTG GCC CTG CGG CTG GCC TGC ATC GGG GAC GAG ATG GAC GTG AGC  
 57 L A L R L A C I G D E M D V S Z1

[SEQ. ID NO: 31]  
 [SEQ. ID NO: 32]

190 \* 200 \*  
 10. ATC GGG GAC GAG ATG  
 64 I G D E M 68

[SEQ. ID NO: 33]  
 [SEQ. ID NO: 34]

FIG. 8C





Fig. 9

# Inhibition of Bcl-xL/ GD domain-mediated binding by GD domain peptides






Fig 11

Inhibition of Bcl-xL protection of FAS/CHX-treated HeLa cells  
by Bak GD domain peptides




Fig. 1